EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-PSO-01(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under Indian medical guidelines, stem cell therapy for Psoriasis & Psoriatic Arthritis is strictly investigational and administered under active Institutional Ethics Committee (IEC) oversight.
Pathophysiology & Disease Context:
Psoriasis is a chronic, immune-mediated inflammatory disorder marked by dysregulated T-cell signaling, excessive cytokine release (IL-17, IL-23, TNF-α), and hyperproliferation of epidermal keratinocytes.
Biological Rationale & Paracrine Action:
Investigates the immunomodulatory and trophic paracrine potential of clinical-grade mesenchymal stem cells to support tissue homeostasis, cellular repair, and inflammatory moderation.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Target Diagnoses: Moderate-to-severe plaque psoriasis, guttate psoriasis, or psoriatic arthritis refractory to topical therapies, phototherapy, and conventional systemic disease-modifying agents (such as methotrexate or biologics).
Mandatory Pre-Procedure Diagnostics:
Pre-Screening Diagnostics: Baseline Psoriasis Area and Severity Index (PASI) or Dermatology Life Quality Index (DLQI) assessment, complete autoimmune panel, complete blood count, and liver/renal profile.
Strict Safety Exclusion Parameters:
Active systemic or cutaneous bacterial/fungal infections, active viral hepatitis or HIV, active malignancy, or concurrent untreated severe tuberculosis.
Triage Protocol & Multi-Specialty Clearance:
Pre-travel multi-disciplinary medical board evaluation and baseline scan review prior to issuing medical visa invitation clearance.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Plaque Clearance: Gradual reduction in erythema, induration, and desquamation across affected skin lesions.
- Symptom Relief: Meaningful decrease in chronic pruritus (itching), burning sensations, and skin tightness.
- Joint Mobility: Modest reduction in peripheral joint tenderness and stiffness in patients with comorbid psoriatic arthritis.
- Remission Intervals: Potential extension of treatment-free intervals alongside standard skin maintenance.
Documented Procedural Risks & Limits:
- Transient low-grade pyrexia, mild headache, or localized infusion-site redness resolving within 24–48 hours.
- Minor infusion-related flushing or vasovagal reactions.
- No Guaranteed Clearance: Disease severity and individual immune profiles vary widely; cell therapy does not alter genetic susceptibility and may not prevent future flare-ups.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited Facilities
Clinical procedures conducted exclusively within tertiary healthcare centers accredited by NABH and JCI.
cGMP Cleanroom Rigor
Cell preparation complies strictly with Indian CDSCO quality standards and international Good Manufacturing Practices.
Specialist Collaboration
Unified case oversight by board-certified dermatologists, rheumatologists, and clinical immunologists.
Ethical Trial Governance
Regulated by an active Institutional Ethics Committee registered with the Department of Health Research (DHR).
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Video Consultation
Detailed telemedicine session with lead dermatologists to evaluate medical history and set realistic expectations.
Government Medical Visa
Fast-track assistance with official Government of India Medical Visa (MED) and Medical Attendant (MED-X) documentation.
Dedicated Case Liaison
Single multilingual point of contact managing scheduling, hospital admission, and translation needs.
Remote Follow-Up Program
Structured virtual evaluations at Months 1, 3, 6, and 12, sharing clinical photo assessments directly with the patient's home dermatologist.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Sanitized Airport Transfers
Private, air-conditioned vehicle pick-up and drop-off to ensure gentle transit for patients with compromised skin integrity.
Inpatient Living
Private hospital suites featuring barrier-free access, hypoallergenic bedding, climate control, and 24/7 specialized nursing care.
Outpatient Partner Stays
Vetted 4-star and 5-star serviced apartments located within 10 minutes of the hospital.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 4 to 5 days structured in-hospital observation pathway.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Psoriasis & Psoriatic Arthritis
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Phase 1/2a Clinical Trial on Allogeneic Umbilical Cord MSCs for Plaque Psoriasis
Cheng, L., Wang, S., Peng, C., et al. (2022). Human umbilical cord-derived mesenchymal stem cell therapy for patients with moderate-to-severe plaque psoriasis: a phase 1/2a randomized, double-blind, placebo-controlled trial. Signal Transduction and Targeted Therapy, 7(1), 327.
Prospective Clinical Trial on Autologous Bone Marrow MSCs in Refractory Psoriasis
Comella, K., Parlo, M., Daly, R., & Dom佣nguez, J. M. (2018). First-in-man intravenous and intradermal administration of autologous adipose-derived stromal vascular fraction and mesenchymal stem cells in psoriasis: a safety and feasibility trial. Journal of Translational Medicine, 16(1), 162.
Long-Term Remission Follow-up of Allogeneic UC-MSCs in Psoriasis Vulgaris
Wang, Z., Wang, Y., & Zhang, J. et al. (2021). Long-term clinical efficacy and immunological mechanisms of umbilical cord mesenchymal stem cell infusion in refractory psoriasis: A 24-month prospective cohort. Cell Transplantation, 30, 09636897211029140.
Systematic Review & Meta-Analysis of MSCs in Immune-Mediated Dermatoses
Shin, L., & Kim, M. et al. (2023). Therapeutic potential and mechanisms of mesenchymal stem cells in psoriasis and atopic dermatitis: A systematic review and meta-analysis of clinical and preclinical trials. Stem Cell Research & Therapy, 14(1), 184.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with the National Guidelines for Stem Cell Research formulated by the Indian Council of Medical Research (ICMR) and directives from the National Medical Commission (NMC), stem cell therapy for Psoriasis is classified as investigational and experimental. It is not recognized by the Central Drugs Standard Control Organisation (CDSCO) as an approved routine commercial treatment or definitive cure. It must be administered strictly within ethics-committee-approved clinical research protocols. Patients are strongly advised never to abruptly discontinue prescribed systemic treatments, biologics, or medical topical regimens without specialist supervision.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.